For the first time all direct acting oral anticoagulants currently licensed for prevention of stroke in people with atrial fibrillation have been ranked in terms of both individual efficacy and safety outcomes and overall cost effectiveness. Despite their higher costs, several are preferable to warfarin as an initial treatment choice, with apixaban (Eliquis) ranking highest ...
DOACs ranked in order of efficacy, safety and cost
By Jennie James
2 May 2018